We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

16 hedge funds and large institutions have $408K invested in Titan Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.35% → 0.33% (-0.02%)

11% less funds holding

Funds holding: 18 → 16 (-2)

18% less capital invested

Capital invested by funds: $498K → $408K (-$89.6K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
16
Holders Change
-2
Holders Change %
-11.11%
% of All Funds
0.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$5.63K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$15.8K
2
TSS
Two Sigma Securities
New York
-$9.34K
3
Renaissance Technologies
Renaissance Technologies
New York
-$149
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29
5
TRCT
Tower Research Capital (TRC)
New York
-$15
Name Holding Trade Value Shares
Change 		Change in
Stake
Truist Financial
1
Truist Financial
North Carolina
$258K – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$56K -$149 -20 -0.3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$33.8K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$29K – – –
State Street
5
State Street
Massachusetts
$15.8K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$8.08K -$15.8K -2,127 -68%
Millennium Management
7
Millennium Management
New York
$6.23K +$5.63K +756 New
TRCT
8
Tower Research Capital (TRC)
New York
$638 -$15 -2 -3%
LFA
9
Level Financial Advisors
New York
$407 – – –
Group One Trading
10
Group One Trading
Illinois
$95 – – –
Bank of America
11
Bank of America
North Carolina
$85 – – –
JP Morgan Chase
12
JP Morgan Chase
New York
$64 – – –
Wells Fargo
13
Wells Fargo
California
$37 – – –
BlackRock
14
BlackRock
New York
$25 – – –
GWSA
15
Global Wealth Strategies & Associates
Colorado
$17 – – –
Osaic Holdings
16
Osaic Holdings
Arizona
$13 -$7 -1 -33%
Morgan Stanley
17
Morgan Stanley
New York
$2 -$7 -1 Closed
NA
18
NewEdge Advisors
Louisiana
$2 – – –
Qube Research & Technologies (QRT)
19
Qube Research & Technologies (QRT)
United Kingdom
$2 – – –
WIM
20
Westside Investment Management
California
$2 – – –
CSC
21
Caldwell Sutter Capital
California
$1 – – –
NFSG
22
Newbridge Financial Services Group
Florida
$1 – – –
UBS Group
23
UBS Group
Switzerland
$1 – – –
TSS
24
Two Sigma Securities
New York
– -$9.34K -985 Closed
Fidelity Investments
25
Fidelity Investments
Massachusetts
– -$29 -3 Closed
1
2

TTNP Hedge Fund Activity: Q4 2023 in Review

16 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2023, worth a combined $408K — down 18% from $498K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of TTNP and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 0 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $5.63K. The largest seller was Susquehanna International Group, cutting an estimated $15.8K.

  • 16 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2023, down from 18 in Q3 2023.
  • Funds reported $408K of Titan Pharmaceuticals stock for Q4 2023, down 18% quarter-over-quarter.
  • 1 fund opened new Titan Pharmaceuticals positions in Q4 2023 and 3 closed out, a net change of -2 holders.
  • The largest Titan Pharmaceuticals buyer in Q4 2023 was Millennium Management, an estimated $5.63K added.
  • The largest Titan Pharmaceuticals seller in Q4 2023 was Susquehanna International Group, an estimated $15.8K sold.

Based on aggregated 13F filings for Q4 2023.